KPV Research & Studies
Part of the full KPV guide - a melanocortin-derived c-terminal tripeptide reference compound, identity-verified with a COA on every vial.
In brief
The KPV research record assembled here rests on four cited sources spanning intestinal cell biology, melanocortin biochemistry, and antimicrobial assays. Rather than restating the mechanism, this spoke maps what each citation and research area actually interrogates at the bench: which cell lines, which transporters, which signaling readouts, and which microbial targets. The cited work clusters around three investigational threads. The first is transporter-mediated uptake and inflammation modulation in cultured intestinal epithelium (Dalmasso et al., Gastroenterology 2008). The second is melanocortin-receptor-independent anti-inflammatory characterization in murine inflammatory bowel disease models (Kannengiesser et al., Inflammatory Bowel Diseases 2008). The third is direct antimicrobial activity of the alpha-MSH C-terminus (Cutuli et al., Journal of Leukocyte Biology 2000). A broader review (Brzoska et al., Endocrine Reviews 2008) situates alpha-MSH and related tripeptides in their biochemistry and in-vitro/in-vivo context. All are preclinical; none establish human efficacy or therapeutic outcomes.
The detail
A closer look
01
Transporter uptake and epithelial signaling
The Dalmasso et al. (Gastroenterology 2008, PMID 18061177) work anchors the PepT1-mediated uptake thread. It examines KPV in cultured intestinal epithelial systems referenced in the entry (Caco2-BBE, HT29-Cl.19A), connecting cellular entry through the proton-coupled oligopeptide transporter PepT1 (SLC15A1) to a reduction in intestinal inflammation in the model. Two research areas map directly onto this source: PepT1 transporter-mediated cellular peptide uptake, and NF-kB pathway modulation in epithelial and immune cell models. The investigational logic is to show that the transporter, which is induced in inflamed epithelium, admits the tripeptide, and that intracellular KPV at nanomolar concentrations lowers cytokine-stimulated NF-kB and MAP kinase activation. This source is the keystone for the transporter-then-signaling model and is the basis for the entry's uptake-route and in-vitro signaling key facts.
02
Receptor-independence in murine IBD models
Kannengiesser et al. (Inflammatory Bowel Diseases 2008, PMID 18092346) supports the melanocortin-receptor-independent signaling research area. The entry attributes to this source the finding that KPV's anti-inflammatory action in cell and animal models appears at least partially independent of MC1R signaling, and that the tripeptide does not drive pigmentation in the manner of full alpha-MSH. The study title frames the tripeptide as having anti-inflammatory potential in murine models of inflammatory bowel disease, which places this work firmly in the preclinical animal-model context rather than human study. For researchers, this citation is what distinguishes KPV's characterized activity from classical melanocortin-receptor pharmacology and provides the receptor-relationship key fact. It remains a preclinical characterization, not a therapeutic-outcome claim.
03
Antimicrobial assays and structure-activity context
Cutuli et al. (Journal of Leukocyte Biology 2000, PMID 10670585) underpins the direct antimicrobial/membrane-interaction research area. The entry attributes to this source that the alpha-MSH C-terminal fragment reduces viability and germ-tube formation of Candida albicans and shows activity against Staphylococcus aureus in vitro. This positions the fragment as having membrane-level effects measurable in microbial assays, separate from its epithelial signaling role. The Brzoska et al. review (Endocrine Reviews 2008, PMID 18612139) provides the broader biochemical and structure-activity backdrop for alpha-MSH and related tripeptides, supporting the structure-activity-relationship research area and the parent-molecule origin fact. Together these sources frame KPV across uptake, signaling, antimicrobial, and structural lines of investigation, all within in-vitro and preclinical contexts.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. KPV is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.